TIAA CREF Individual & Institutional Services LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 10.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,498 shares of the company’s stock after buying an additional 12,109 shares during the period. TIAA CREF Individual & Institutional Services LLC’s holdings in Merck & Co., Inc. were worth $18,672,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of MRK. BlackRock Inc. increased its stake in shares of Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares during the period. State Street Corp raised its holdings in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after purchasing an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP raised its holdings in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Merck & Co., Inc. by 8.3% during the third quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock worth $6,059,345,000 after purchasing an additional 3,183,169 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. Freedom Broker upped their target price on Merck & Co., Inc. from $125.00 to $140.00 and gave the stock a “hold” rating in a research report on Monday, November 2nd. Wolfe Research lifted their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Weiss Ratings upgraded Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 7th. Finally, Cantor Fitzgerald boosted their price objective on Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $155.74.
Check Out Our Latest Analysis on MRK
Merck & Co., Inc. Stock Performance
NYSE:MRK opened at $133.56 on Friday. Merck & Co., Inc. has a twelve month low of $95.36 and a twelve month high of $156.92. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. The company has a 50-day moving average of $145.28 and a 200-day moving average of $129.29. The firm has a market cap of $329.26 billion, a price-to-earnings ratio of 137.69, a price-to-earnings-growth ratio of 6.62 and a beta of 0.13.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. During the same quarter in the previous year, the company posted $2.58 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. Analysts forecast that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.88 per share. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.85. This represents a $3.52 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, December 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 350.52%.
Key Merck & Co., Inc. News
These are some of the MRK news items that stood out recently:
- Positive Sentiment: Merck said its TroFuse-015 trial of sac-TMT met its primary overall-survival endpoint in patients with advanced gastroesophageal adenocarcinoma who had received at least two prior lines of treatment. The result adds encouraging evidence for a potential oncology product. Reuters: Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial
- Positive Sentiment: A German court overturned an injunction that had restricted Merck from distributing and offering Keytruda SC in Germany. The ruling removes an immediate obstacle to the formulation, although Halozyme says it will pursue a new patent lawsuit. Zacks: HALO Faces Legal Setback in Germany Over MRK's Keytruda SC
- Positive Sentiment: Merck partnered with Isomorphic Labs to discover small-molecule oncology drug candidates, combining the AI drug-design company’s approach with Merck’s data and drug-development expertise. The collaboration could support longer-term growth as Merck prepares for Keytruda’s eventual patent expiry. Business Wire: Merck and Isomorphic Labs Enter Strategic Research Collaboration
Insiders Place Their Bets
In related news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares in the company, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.17% of the company’s stock.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
